Radically different
Nature Medicine, Published online: 22 April 2026; doi:10.1038/s41591-026-04356-z
The analysis of the 100 Million Brazilian database reveals that a past tuberculosis diagnosis increases the risk of death up to 14 years later regardless of treatment outcome, which should prompt urgent prioritization of global prevention efforts.
Nature Medicine, Published online: 22 April 2026; doi:10.1038/s41591-026-04308-7
The authors propose five high-priority areas to close the current gaps in diagnostic testing, providing a path to self-reliance in health security and universal healthcare in Africa.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Big news: I’ve convinced at least one other STAT staffer to re-read “The Odyssey” with me ahead of the movie this summer. Starting today, that means we’ll read three books (chapters), or about 1,500 lines, per week for the next eight weeks. Care to join us?
Have you ever wondered how many drugs are behind the counter at your local pharmacy?
According to Thomas Goetz — a journalist, entrepreneur, and host of the new podcast “Drug Story” — “there are over 3,000 drugs behind a typical pharmacist counter.” And behind each drug is a story.
Dr. Shinya Yamanaka is recognized for the generation of induced pluripotent stem cells (iPSCs) from fibroblasts by a combination of multiple transcription factors, and he won the Nobel Prize in Physiology or Medicine in 2012 jointly with Sir John B. Gurdon for this discovery. Twenty years after the discovery, the Cell Reports Medicine editorial team discusses with Dr. Yamanaka the scientific, technical, and translational milestones that have shaped the field of regenerative medicine. We also discuss the role of iPSCs in disease modeling and drug discovery, the interplay with genome editing, and ongoing issues that still prevent the widespread clinical application of iPSC-derived therapies.
Bellut et al. show that the NLRP3 inflammasome drives hyperacute inflammation and infarct progression during large vessel occlusion in stroke. Pharmacological inhibition reduces infarct growth in mice. NLRP3-positive cells in human pial blood before thrombectomy correlate with clinical outcome and highlight a potential therapeutic target prior to recanalization.
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes.
Now the test is whether the drug, called fenebrutinib, can win the regulatory green light.
While three late-stage trials of the drug have shown it to be effective, analysts have homed in on some potentially worrying liver safety signals, an issue that previously prompted the Food and Drug Administration to reject an MS therapy developed by Sanofi. In data released Tuesday, researchers also disclosed that there were two drug-related deaths among patients who took fenebrutinib.